TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Guidance & Earnings Results
On 2026-07-29 TEVA PHARMACEUTICAL INDUSTRIES LTD raised guidance: "2026 revenues $16.5-$16.85B; non-GAAP operating income $3.8-$4.0B; non-GAAP diluted EPS $1.91-$2.11; FCF…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TEVATEVA PHARMACEUTICAL INDUSTRIES LTDFollow TEVA — free
—
Price chart with a free account
- Market cap
- 45.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Raised | 2026 revenues $16.5-$16.85B; non-GAAP operating income $3.8-$4.0B; non-GAAP diluted EPS $1.91-$2.11; FCF $2.0-$2.4B · full year |
| 29 Apr 26 | Reaffirmed | FY2026 revenue $16.4-16.8B; non-GAAP operating income $3.80-4.0B (stand-alone $4.55-4.8B); adjusted EBITDA $4.23-4.53B (stand-alone $5.0-5.3B); non-GAAP diluted EPS $1.91-2.11 (stand-alone $2.57-2.77); free cash flow $2.0-2.4B; non-GAAP tax rate 20-23% (stand-alone 16-19%) · full year |
| 28 Jan 26 | Mixed | FY2026 revenue $16.4-16.8B (midpoint $16.6B vs FY2025 $17.3B); non-GAAP operating income $4.55-4.8B; adjusted EBITDA $5.0-5.3B; non-GAAP diluted EPS $2.57-2.77; free cash flow $2.0-2.4B; capex ~$0.5B; AUSTEDO $2.4-2.55B; AJOVY $750-790M; UZEDY $250-280M; finance expenses ~$800M; tax rate 16-19% · full year |
| 12 Jan 26 | Reaffirmed | FY2025 revenue $16.8-17.0B; operating margin ~26.2-27.1%; adjusted EBITDA $4.8-5.0B; diluted EPS $2.55-2.65; free cash flow $1.6-1.9B; net leverage ~2.5-2.9x; tax rate 15-18%. FY2026 revenue flat to slightly down vs 2025; FY2027 low-single digit growth; FY2030 mid-single digit CAGR. FY2026 operating profit growing vs 2025; FY2027 30%; FY2030 >30%. FY2026 adjusted EBITDA growing vs 2025; FY2027 gro · full year |
| 5 Nov 25 | Raised | FY25 AUSTEDO revenue raised to $2.05-2.15B from $2.0-2.05B; FY25 revenue tightened to $16.8-17.0B from $16.8-17.2B; FY25 non-GAAP EPS raised to $2.55-2.65 from $2.50-2.60; FY25 non-GAAP operating income raised to $4.4-4.6B from $4.3-4.6B; FY25 adjusted EBITDA raised to $4.8-5.0B from $4.7-5.0B; FY25 free cash flow unchanged at $1.6-1.9B · full year |
| 30 Jul 25 | Raised | FY2025 AUSTEDO revenue raised to $2,000M-$2,050M from $1,905M-$1,955M; AJOVY raised to $630M-$640M from $535M-$545M; UZEDY raised to $190M-$200M from $95M-$105M; Non-GAAP EPS raised to $2.50-$2.65 from $2.45-$2.65; Revenue $16.8B-$17.2B reaffirmed; Non-GAAP operating income $4.3B-$4.6B reaffirmed; Adjusted EBITDA $4.7B-$5.0B reaffirmed; FCF $1.6B-$1.9B reaffirmed · full year |
TEVA PHARMACEUTICAL INDUSTRIES LTD — questions
- What guidance did TEVA PHARMACEUTICAL INDUSTRIES LTD give?
- On 2026-07-29: "2026 revenues $16.5-$16.85B; non-GAAP operating income $3.8-$4.0B; non-GAAP diluted EPS $1.91-$2.11; FCF $2.0-$2.4B"
- When does TEVA PHARMACEUTICAL INDUSTRIES LTD report earnings?
- TEVA PHARMACEUTICAL INDUSTRIES LTD's next earnings report is expected on 2026-11-03.
Every figure on this page comes from TEVA PHARMACEUTICAL INDUSTRIES LTD's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.